OBJECTIVES

After successful completion of this activity, participants should be able to:

• List recent advances in IBD epidemiology and genetics
• Describe important considerations in the pharmacological therapy for IBD
• Review recent advances in the understanding of IBD pathophysiology from basic research studies
• Delineate the role of serologic biomarkers in the management of IBD
  
• Recommend management options based on current understanding of clinical trial data
  
• Formulate an appropriate strategy for the management of IBD in pregnancy
  
• List important advances in the use of biologics and immunomodulators in the treatment of IBD
  
• Describe important aspects of managing IBD patients, including ethical dilemmas in clinical trials, adolescent patient management, and pain control